deidentified clinformatics data mart database cdm (Optum Inc)
86
Structured Review
Optum Inc
deidentified clinformatics data mart database cdm
Deidentified Clinformatics Data Mart Database Cdm, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/deidentified+database/clinformatics+data+database+mart/pmc13157083-146-10-9
Average 86 stars, based on 1 article reviews
Deidentified Clinformatics Data Mart Database Cdm, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/deidentified+database/clinformatics+data+database+mart/pmc13157083-146-10-9
Average 86 stars, based on 1 article reviews
deidentified clinformatics data mart database cdm - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations. Article Snippet: METHODS Study design and participants This was a retrospective cohort study of US patients hospitalised with a viral LRTD from 1 January 2015 to 31 March 2023 using Optum’s deidentified Article Title: Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations. Article Snippet: Ethics approval All data in Article Title: Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations. Article Snippet: All data in Article Title: Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations. Article Snippet: Methods In this retrospective analysis, adults hospitalised between 1 January 2015 and 31 March 2023 were identified using Article Title: Psychosocial factors, guideline-directed medical therapy, and healthcare resource use among patients newly diagnosed with heart failure in the United States Article Snippet: This study was conducted using claims data from the Article Title: Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant Erwinia in pediatrics and adolescents/young adults with acute lymphoblastic leukemia. Article Snippet: Materials and methods: This was a retrospective study using |